Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IGF1 modulates lesional skin inflammation in checkpoint inhibitor-induced lichen planus.

bioRxiv : the preprint server for biology·2026
Same author

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.

Cancer·2026
Same author

Postoperative Outcomes in Dermatologic Surgery Among Patients Receiving VEGF and VEGFR Inhibitors: A Propensity-Matched Real-World Analysis.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026
Same author

Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors.

Journal for immunotherapy of cancer·2025
Same author

Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Cutaneous toxicities secondary to STAT3 inhibition: A retrospective case series.

JAAD case reports·2025
Same journal

Pellagra associated with iron deficiency.

Dermatology online journal·2026
Same journal

Demodicosis: A frequently underrecognized cause of recalcitrant ear pruritus.

Dermatology online journal·2026
Same journal

Association of alopecia areata with COVID-19 vaccination: A vaccine adverse events reporting system analysis.

Dermatology online journal·2026
Same journal

Gender based price differences in 5% minoxidil foam: The impact of generic alternatives and bulk packaging.

Dermatology online journal·2026
Same journal

Retrospective analysis of filler complications reported in the manufacturer and user facility device experience database from 2015 to 2025.

Dermatology online journal·2026
Same journal

Characterizing barriers to care in patients with hidradenitis suppurativa.

Dermatology online journal·2026
See all related articles

Related Experiment Video

Updated: Mar 15, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

604

Regorafenib- associated panniculitis.

Ramya Chockalingam, Phyu Aung, Anisha B Patel1

  • 1Department of Dermatology, University of Texas Medical School at Houston and MD Anderson Cancer Center. apatel11@mdanderson.org.

Dermatology Online Journal
|September 13, 2016
PubMed
Summary
This summary is machine-generated.

Regorafenib, a cancer drug, can cause a rare skin condition called panniculitis. This case report describes a new side effect of regorafenib, aiding in faster diagnosis.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.3K

Related Experiment Videos

Last Updated: Mar 15, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

604
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.3K

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Regorafenib is a multikinase inhibitor used for metastatic colon cancer and gastrointestinal stromal tumors.
  • Common side effects include hand-foot skin reaction, alopecia, and oral mucositis.

Observation:

  • A 60-year-old woman developed panniculitis after six months of regorafenib therapy.
  • The panniculitis presented as lobular and septal granulomatous inflammation.

Findings:

  • Biopsy revealed granulomatous inflammation, fibrosis, lymphohistiocytic infiltrate, and fat necrosis.
  • This represents a previously undescribed side effect of regorafenib.

Implications:

  • Awareness of regorafenib-induced panniculitis can lead to earlier diagnosis.
  • This finding expands the known side effect profile of regorafenib.
  • Facilitates timely management of this rare adverse event.